Intra-Patient Variability of Tacrolimus in Kidney Transplant Patients at Bhumirajanagarindra Kidney Institute Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210519005

Enrollment

100

Registered

2021-05-19

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant patients Kidney Transplantation Tacrolimus Variability

Interventions

Kidney transplant patients who receive tacrolimus as a standard immunosuppressive therapy

Treatment

Patients receiving tacrolimus

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. New kidney transplant patients who received living donor or deceased donor 2. Patients receiving tacrolimus as immunosuppression after transplantation

Exclusion criteria

Exclusion criteria: 1. Patients with multiple organ transplantation 2. Patients having allograft with primary non-function 3. Patients having conditions affecting tacrolimus level 4. Incomplete information for study evaluation

Design outcomes

Primary

Measure	Time frame
Intra-patient variability of tacrolimus 12 months after transplantation Intra-patient variability of minimum tacrolimus concentration	—

Secondary

Measure	Time frame
Renal function 12 months after transplant eGFR by CKD-EPI equation,Rate of biopsy proven acute rejection (BPAR) 12 months after transplantation Diagnosis of BPAR by physician,Rate of infection 12 months after transplantation Diagnosis of any infection	—

Countries

Thailand

Contacts

Public ContactTeerayuth Jiamjariyaporn

Bhumirajanagarindra Kidney Institute

teerayut.bki@gmail.com66618508778

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026